Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Overview
- Phase
- Phase 3
- Intervention
- Stereotactic Body Radiation Therapy
- Conditions
- Not specified
- Sponsor
- NRG Oncology
- Enrollment
- 692
- Locations
- 377
- Primary Endpoint
- Incidence of patients-reported gastrointestinal and genitourinary toxicity
- Status
- Active, Not Recruiting
- Last Updated
- 3 months ago
Overview
Brief Summary
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related Quality of Life (HRQOL) as measured by Expanded Prostate Cancer Index Composite (EPIC)-26 at 24 months post completion of therapy. II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy or 20 fractions of 3 Gy) as measured by disease free survival (DFS). SECONDARY OBJECTIVES: I. To determine whether SBRT can be shown to be superior to hypofractionated IMRT at 12 and 24 months post completion of therapy in terms of HRQOL by having fewer patients that experience a minimal important decline (MID) bowel (12 months only) sexual, hormonal, urinary irritation/obstructive (12 months only) and in urinary incontinence HRQOL as measured by EPIC-26. II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy or 20 fractions of 3 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases. III. To determine the correspondence between the diagnostic magnetic resonance imaging (MRI) and biopsy. IV. To determine if prostate imaging-reporting and data system (PIRADS)version (v)2.1 = 4/5 disease is prognostic for biochemical failure. EXPLORATORY OBJECTIVES: I. To determine whether a potentially more expensive therapy, SBRT, would be cost-effective than standard hypofractionated IMRT as measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L). II. To determine if disease characteristics captured on baseline and follow-up MRI can be used to predict which patients will respond to SBRT versus hypofractionated IMRT. III. To validate autosegmentation tools for the prostate and tumors. IV. Collect specimens for future translational research analyses. OUTLINE: Patients are randomized into 1 of 2 arms. ARM I: Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days. ARM II: Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Previously untreated (no local therapy such as surgery, radiation cryotherapy, high-intensity focused ultrasound \[HIFU\], etc.) localized adenocarcinoma of the prostate with the following clinical findings:
- •Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland); (American Joint Committee on Cancer \[AJCC\], version 7) or cT1a-c or 2a or 2b
- •Stages T1a-T1b are eligible if patient underwent transurethral prostatic resection (TURP)
- •The patient must meet one of the following 3 criteria: 1) Gleason score must be Gleason 7(3+4) with a PSA \< 20 ng/mL, or 2) Gleason 6 (3+3) with a PSA \> 10 ng/mL and \< 20 ng/mL which is considered intermediate risk and eligible for the study (AJCC, version 7), or 3) Group Grade 1 with a PSA \> 10 ng/mL and \< 20 ng/mL or 2 with a PSA \< 20 ng/mL
- •If patient is receiving a 5-alpha reductase inhibitor at the time of enrollment, the baseline PSA value may be double the initial value and the medication should be discontinued but a washout period is not required; to be eligible, a PSA drawn while still on the medicine must be:
- •\< 10 ng/mL if Gleason 7(3+4) (note this patient would be on stratification level 1 if PSA \< 5 ng/mL and stratification level 2 if less than 10 ng/mL)
- •\> 5 ng/mL and less than 10 ng/mL for Gleason 6(3+3) (note this patient would be on stratification level 3)
- •The prostate volume must be \< 70 cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan
- •Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements
- •Age \>= 18
Exclusion Criteria
- •Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis
- •Definitive T3 disease on MRI
- •Prior or current invasive malignancy with current evidence of active disease within the past 2 years
- •Exceptions: Non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma
- •Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment for at least 3 years
- •Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- •The use of hormonal therapy is not allowed; if the patient is on a 5-alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate
- •Severe, active co-morbidity defined as follows:
- •Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
Arms & Interventions
Arm II (SBRT)
Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.
Intervention: Stereotactic Body Radiation Therapy
Arm I (IMRT)
Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.
Intervention: Intensity-Modulated Radiation Therapy
Arm I (IMRT)
Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.
Intervention: Quality-of-Life Assessment
Arm I (IMRT)
Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.
Intervention: Questionnaire Administration
Arm II (SBRT)
Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.
Intervention: Quality-of-Life Assessment
Arm II (SBRT)
Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.
Intervention: Questionnaire Administration
Outcomes
Primary Outcomes
Incidence of patients-reported gastrointestinal and genitourinary toxicity
Time Frame: Up to 2 years
Will be measured by Expanded Prostate Cancer Index Composite-(EPIC) 26 bowel and urinary irritation domains. Will be compared between treatment arms using a test of proportions with two-sided significance level of 0.05.
Disease free survival
Time Frame: Time to biochemical failure (Phoenix definition), local failure, regional failure, distant metastasis, or death from any cause, assessed up to 2 years
Will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test.
Secondary Outcomes
- Health related quality of life(Up to 2 years)
- Regional failure(From the time of randomization to the date of local failure, date of precluding death, or last known follow-up date, assessed for up to 2 years)
- Distant metastasis(From the time of randomization to the date of distant metastasis, date of precluding death, or last known follow-up date, assessed for up to 2 years)
- Prostate cancer specific survival(Up to 2 years)
- Biochemical failure(Up to 2 years)
- Local failure(From the time of randomization to the date of local failure, date of precluding death, or last known follow-up date, assessed for up to 2 years)
- Incidence of adverse events (AEs)(Up to 2 years)
- Presence of Prostate Imaging-Reporting and Data System version (PIRADSv) 2 = 4/5 disease(Baseline)
- Predictive value of PIRADSv2 = 4/5 disease for biochemical failure(Up to 2 years)
- Overall survival(From the date of randomization to the date of death or last known follow-up date, with patients alive at the last known follow-up time treated as censored, assessed up to 5 years)